Literature DB >> 28346727

Sulforaphene enhances radiosensitivity of hepatocellular carcinoma through suppression of the NF-κB pathway.

Kewei Ren1,2,3, Zhen Li1,2,3, Yahua Li1,2,3, Wenzhe Zhang1,2,3, Xinwei Han1,2,3.   

Abstract

Sulforaphene (SFE), a naturally occurring isothiocyanate found in cruciferous vegetables, has attracted increasing attention for its anti-cancer effect in many cancers, including hepatocellular carcinoma (HCC). However, the precise role of SFE in the radiosensitivity of HCC is still unclear. Here, cell proliferation and apoptosis were detected by MTT and flow cytometry assay, respectively. The activity of NF-κB was further evaluated by ELISA. We also observed the effect of SFE and/or radiation on tumor growth. The results showed that SFE inhibited cell proliferation and induced apoptosis in HCC cells. Radiation increased NF-kB activity, while PDTC, a NF-kB inhibitor, enhanced radiation-induced cell death. SFE inhibited NF-kB activity and the downstream gene expressions of the NF-kB pathway in HCC cells. Moreover, SFE enhanced the inhibitory effect of radiation on tumor growth both in vitro and in vivo. This study indicated that SFE sensitized the radiosensitivity of HCC by blocking the NF-kB pathway.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  NF-κB pathway; hepatocellular carcinoma; radiosensitivity; sulforaphene

Mesh:

Substances:

Year:  2017        PMID: 28346727     DOI: 10.1002/jbt.21917

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  8 in total

1.  Activation of PTGS2/NF-κB signaling pathway enhances radiation resistance of glioma.

Authors:  Cheng Tan; Liang Liu; Xiaoyang Liu; Ling Qi; Weiyao Wang; Guifang Zhao; Libo Wang; Yimeng Dai
Journal:  Cancer Med       Date:  2019-02-10       Impact factor: 4.452

Review 2.  The Glucosinolates: A Sulphur Glucoside Family of Mustard Anti-Tumour and Antimicrobial Phytochemicals of Potential Therapeutic Application.

Authors:  James Melrose
Journal:  Biomedicines       Date:  2019-08-19

3.  Network Pharmacology Integrated with Transcriptomics Deciphered the Potential Mechanism of Codonopsis pilosula against Hepatocellular Carcinoma.

Authors:  Zhili Liu; Yuzhe Sun; Hefu Zhen; Chao Nie
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-27       Impact factor: 2.629

4.  Treatment of Human Glioblastoma U251 Cells with Sulforaphane and a Peptide Nucleic Acid (PNA) Targeting miR-15b-5p: Synergistic Effects on Induction of Apoptosis.

Authors:  Jessica Gasparello; Chiara Papi; Matteo Zurlo; Laura Gambari; Andrea Rozzi; Alex Manicardi; Roberto Corradini; Roberto Gambari; Alessia Finotti
Journal:  Molecules       Date:  2022-02-15       Impact factor: 4.411

5.  Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling.

Authors:  Peng Liu; Samuel J Atkinson; Sophia E Akbareian; Zhigang Zhou; Andrea Munsterberg; Stephen D Robinson; Yongping Bao
Journal:  Sci Rep       Date:  2017-10-04       Impact factor: 4.379

6.  Sulforaphene induces apoptosis and inhibits the invasion of esophageal cancer cells through MSK2/CREB/Bcl-2 and cadherin pathway in vivo and in vitro.

Authors:  Chengjuan Zhang; Junxia Zhang; Qiong Wu; Benling Xu; Guoguo Jin; Yan Qiao; Simin Zhao; Yang Yang; Jinwen Shang; Xiaofang Li; Kangdong Liu
Journal:  Cancer Cell Int       Date:  2019-12-19       Impact factor: 5.722

7.  Tripartite Motif-Containing 46 Promotes Viability and Inhibits Apoptosis of Osteosarcoma Cells by Activating NF-B Signaling Through Ubiquitination of PPAR.

Authors:  Wenwei Jiang; Xinyu Cai; Tianyang Xu; Kaiyuan Liu; Dong Yang; Lin Fan; Guodong Li; Xiao Yu
Journal:  Oncol Res       Date:  2020-04-15       Impact factor: 5.574

Review 8.  Sulforaphane: Expected to Become a Novel Antitumor Compound.

Authors:  Geting Wu; Yuanliang Yan; Yangying Zhou; Yumei Duan; Shuangshuang Zeng; Xiang Wang; Wei Lin; Chunlin Ou; Jianhua Zhou; Zhijie Xu
Journal:  Oncol Res       Date:  2020-02-28       Impact factor: 5.574

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.